Table 4. Outcomes after repeat CRS/HIPEC for colorectal primaries.
Author (citation) | Study type | Year | N | PCI | Median overall survival (months) | Median follow-up (months) | Morbidity (grade 3 and 4) | Mortality | CC 0-1 |
---|---|---|---|---|---|---|---|---|---|
Portilla et al. (31) | R | 1999 | 18 | >12 (44.4%) | 20.0 | 71.0 | 25.0% | 0.0% | 77.8% |
Glehen et al. (32) | R | 2004 | 506 | NA | 57.6 (2nd) | 53.0 | 22.9% | 4.0% | 74.5% |
Kianmanesh et al. (33) | R | 2007 | 43 | Gilly III-IV 77% | 38.4 | NA | 39.0% (all grades) | 2.3% | 70.0% |
Bijelic et al. (34) | R | 2007 | 49 | 15 (mean) | 30.0 | 29.5 | NA | NA | 69.2% |
Goéré et al. (35) | R | 2015 | 139 | 11 (mean) | 3-year survival 52.0% | 60.0 | 23.0% intra-abdominal; 44.6% extra-abdominal | 6.0% | 100.0% |
Williams et al. (36) | Review | 2014 | 18 | 5 (median) | 22.6 (2nd) | NA | 16.7% | 0.0% | 88.9% |
Braam et al. (37) | R | 2014 | 32 | NA | 43.0 | 26.6 | 22.0% | 3.1% | NA |
CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; R, retrospective; N, number of patients; PCI, peritoneal cancer index; CC, completeness of cytoreduction; NA, not available.